8-K: Panacea Life Sciences Sells PUR Life Medical Assets to Related Party for $180,000 Note

Panacea Life Sciences has sold its PUR Life Medical System assets to PLM Holdings, a related party, for a $180,000 promissory note, also transferring associated liabilities.

Summary

• Panacea Life Sciences initially agreed to purchase PUR Life Medical assets for up to $2.6 million, including an initial deposit of $180,000.
• A release agreement was made to rescind the initial purchase, with PUR Life required to return the $180,000 deposit by November 14, 2023.
• PUR Life failed to return the deposit, so Panacea retained ownership of the PUR Life assets and the remaining contingent payments were voided.
• On January 29, 2024, Panacea sold the PUR Life Medical System assets to PLM Holdings for a $180,000 promissory note.
• PLM Holdings also assumed all liabilities related to the PUR Life Medical System franchise and area representative agreements.
• The transaction is considered a related party transaction as PLM Holdings is controlled by Panacea's directors and officers.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company has divested assets and liabilities, the related party nature of the transaction and the relatively low value of the sale raise some concerns. The company has effectively recovered the initial deposit, but the future value of the promissory note is uncertain.

Positives

• Panacea Life Sciences has removed the liabilities associated with the PUR Life Medical System from its balance sheet.
• The company received a $180,000 promissory note from PLM Holdings as compensation for the assets.

Negatives

• The sale of the PUR Life Medical System assets was for a relatively small amount of $180,000.
• The transaction is a related party transaction, which may raise concerns about fairness and potential conflicts of interest.

Risks

• The related party nature of the transaction could lead to scrutiny from regulators and investors.
• The value of the promissory note may be subject to the financial health of PLM Holdings.
• The company has effectively divested itself of the PUR Life Medical System, which may have had future potential.

Future Outlook

The document does not provide any specific forward-looking statements or guidance beyond the completion of the asset sale.

Management Comments

• Leslie Buttorff, the company's CEO and director, is also a shareholder and director of PLM Holdings.
• Nick Cavarra, the president of the company, is also a shareholder and director of PLM Holdings.

Industry Context

The sale of assets to a related party is not uncommon, but it often attracts scrutiny from investors and regulators. The transaction suggests a potential shift in Panacea's strategy, moving away from the PUR Life Medical System.

Comparison to Industry Standards

• It is difficult to compare this specific transaction to industry standards without more information on the value of the PUR Life Medical System assets.
• Related party transactions are generally viewed with caution, and the terms of the deal will be closely examined by investors.
• The use of a promissory note as consideration is a common practice in asset sales, but the risk associated with the note depends on the financial health of the issuer, PLM Holdings.

Related Party Transactions

• The asset sale to PLM Holdings is a related party transaction as the control persons of PLM Holdings are directors, officers, and shareholders of Panacea Life Sciences.

Stakeholder Impact

• Shareholders may be concerned about the related party nature of the transaction and the relatively low value of the sale.
• Employees of the PUR Life Medical System may be impacted by the change in ownership.
• Customers and suppliers of the PUR Life Medical System will now be dealing with PLM Holdings.

Key Dates

Keywords

asset sale, related party transaction, promissory note, PUR Life Medical, PLM Holdings, liabilities, franchise agreements, intellectual property